AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8902152 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet (SAT)
Number of subjects: 19
Study 8902152 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid diet (PUFA)
Number of subjects: 19
Study 1665400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep‐B Vax vaccine administered at 0, 1, and 6 months after birth (5 or 2.5 micrograms in pilot study, 5 micrograms in main study)
Number of subjects: 38000
Study 1665400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep‐B Vax vaccine
Number of subjects: 38000
Study 1665400 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 38000
Study 6241271 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused hemodialyzed patients
Number of subjects: 29
Study 6241271 — intervention group
Group type: COMPARATOR
Intervention: Both transfused and nontransfused hemodialyzed subjects
Number of subjects: 29
Study 31656954 — intervention group
Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 0
Study 31656954 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 0
Study 31656954 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenience sample of women
Number of subjects: 0
Study 31656954 — intervention group
Group type: EXPERIMENTAL
Intervention: Providers
Number of subjects: 0
Study 29410192 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 36
Study 29410192 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 36
Study 27025835 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg + Sofosbuvir (SOF) 400 mg for 12 weeks
Number of subjects: 151
Study 24925124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic load (LGL) breakfast
Number of subjects: 65
Study 24925124 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic load (HGL) breakfast
Number of subjects: 65
Study 24925124 — intervention group
Group type: COMPARATOR
Intervention: No energy control
Number of subjects: 65
Study 22931582 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A H1N1/2009 vaccine
Number of subjects: 30
Study 20538134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) plus Simvastatin (40 mg)
Number of subjects: 1570
Study 17933700 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 600 mg BID + Ritonavir 100 mg BID
Number of subjects: 14
Study 17933700 — intervention group
Group type: COMPARATOR
Intervention: Indinavir 400 mg BID + Ritonavir 100 mg BID
Number of subjects: 14
Study 15686782 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with anti‐anginal drugs (not specified which drugs or dosages)
Number of subjects: 7669
Study 15686782 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatments (not specified)
Number of subjects: 7669
Study 12069465 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) group
Number of subjects: 165
Study 12069465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 9867093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol (F-S) mixture (25 g fructose and 5 g sorbitol)
Number of subjects: 15
Study 9867093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol (F-S) malabsorption
Number of subjects: 15
Study 9867093 — intervention group
Group type: COMPARATOR
Intervention: Jejunal hypersensitivity
Number of subjects: 15
Study 9867093 — intervention group
Group type: COMPARATOR
Intervention: Jejunal dysmotility
Number of subjects: 15
Study 9867093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative symptom scores and breath hydrogen production
Number of subjects: 15
Study 7608320 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 12
Study 7608320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7608320 — intervention group
Group type: COMPARATOR
Intervention: Control (without EMLA)
Number of subjects: 12
Study 2633458 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg molsidomine
Number of subjects: 0
Study 2633458 — intervention group
Group type: COMPARATOR
Intervention: 120 mg isosorbide dinitrate retard
Number of subjects: 0
Study 2633458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 334229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 37
Study 334229 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 37
Study 30578462 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban (35–42 days)
Number of subjects: 0
Study 30578462 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (6–14 days)
Number of subjects: 0
Study 29903591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (aerobic and resistance exercises)
Number of subjects: 58
Study 29903591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 26832435 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 2090
Study 26832435 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressings
Number of subjects: 2090
Study 24276307 — intervention group
Group type: EXPERIMENTAL
Intervention: High Training Load (HTL)
Number of subjects: 14
Study 24276307 — intervention group
Group type: COMPARATOR
Intervention: Moderate Training Load (MTL)
Number of subjects: 14
Study 22674141 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 12.5 mg once daily for 2 weeks
Number of subjects: 38
Study 22674141 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily for 2 weeks
Number of subjects: 38
Study 22674141 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 37.5 mg once daily for 2 weeks
Number of subjects: 38
Study 22674141 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study 20953062 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80mg/day) for 3 weeks
Number of subjects: 13
Study 20953062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17403003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (20 mg) every 5 min
Number of subjects: 175
Study 17403003 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation using meperidine and diazepam
Number of subjects: 175
Study 15694808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 36
Study 15694808 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 36
Study 15694808 — intervention group
Group type: COMPARATOR
Intervention: Sharp dissection with ligation
Number of subjects: 36
Study 12070543 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850mg twice daily) plus Clomiphene citrate (50mg, increasing to 200mg)
Number of subjects: 28
Study 12070543 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Clomiphene citrate (50mg, increasing to 200mg)
Number of subjects: 28
Study 10472229 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic interventions classified by evidence level
Number of subjects: 0
Study 7670451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate supplementation (10 g of lactate as calcium, sodium, and potassium salts, twice a day for 3 weeks)
Number of subjects: 15
Study 7670451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, twice a day for 3 weeks)
Number of subjects: 15
Study 2073113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine at 20 micrograms/liter of air for 12 hours daily for 3 days
Number of subjects: 9
Study 2073113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine at 40 micrograms/liter of air
Number of subjects: 9
Study 2073113 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of rimantadine at 200 mg
Number of subjects: 9
Study 2073113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine at 20 micrograms/liter of air
Number of subjects: 9
Study 7015789 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 46
Study 7015789 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 46
Study 29618226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus muscle reapproximation
Number of subjects: 280
Study 29618226 — intervention group
Group type: COMPARATOR
Intervention: No rectus muscle reapproximation
Number of subjects: 280
Study 28435222 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg dexmedetomidine (BD group)
Number of subjects: 50
Study 28435222 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL 0.9% normal saline (BN group)
Number of subjects: 50
Study 26486256 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in diet self‐efficacy among AA women
Number of subjects: 588
Study 26486256 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in diet‐related social support and self‐efficacy, and family support to exercise among AA men
Number of subjects: 588
Study 26486256 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in friends' support to exercise and exercise‐related self‐efficacy among non‐AA women
Number of subjects: 588
Study 26486256 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in diet self‐efficacy among non‐AA men
Number of subjects: 588
Study 23939663 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted simvastatin doses (ranging from 25 to 80 mg)
Number of subjects: 18
Study 23939663 — intervention group
Group type: COMPARATOR
Intervention: Standard simvastatin dose (40 mg)
Number of subjects: 18
Study 23939663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adapted simvastatin dose (12 mg) during CYP3A inhibition with ritonavir
Number of subjects: 18
Study 20933491 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC plus albendazole (DEC/ALB) combination
Number of subjects: 170
Study 20933491 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 170
Study 20933491 — intervention group
Group type: COMPARATOR
Intervention: DEC
Number of subjects: 170
Study 20933491 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 170
Study 18613316 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance label on powdered infant milk formula
Number of subjects: 0
Study 18613316 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of safe‐handling information
Number of subjects: 0
Study 18613316 — intervention group
Group type: COMPARATOR
Intervention: Ambiguity with incidence rate information
Number of subjects: 0
Study 17704976 — intervention group
Group type: EXPERIMENTAL
Intervention: STW 5/Iberogast
Number of subjects: 0
Study 15065831 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 23
Study 15065831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10567866 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 26
Study 10567866 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrop
Number of subjects: 26
Study 8690148 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic hypoglycemia (2.6 +/- 0.1 mmol/l, 47 +/- 1 mg/dl)
Number of subjects: 16
Study 8690148 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic euglycemia (4.8 +/- 0.1 mmol/l, 86 +/- 5 mg/dl)
Number of subjects: 16
Study 8690148 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped hypoglycemic clamps (4.7, 4.2, 3.6, 3.0, 2.8, 2.5, and 2.2 mmol/l)
Number of subjects: 16
Study 8690148 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped hypoglycemic clamps
Number of subjects: 16
Study 1707413 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (Lomoparan) 750 units subcutaneously every twelve hours until the ninth postoperative day
Number of subjects: 263
Study 1707413 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 263
Study 7163015 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (viewed catheterization videotape)
Number of subjects: 53
Study 7163015 — intervention group
Group type: COMPARATOR
Intervention: Control group (viewed unrelated control videotape)
Number of subjects: 53
Study 30666834 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC-prognosis
Number of subjects: 586
Study 30666834 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI status
Number of subjects: 586
Study 30666834 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC-Prediction
Number of subjects: 586
Study 29096682 — intervention group
Group type: EXPERIMENTAL
Intervention: GEE log‐binomial model
Number of subjects: 50
Study 29096682 — intervention group
Group type: EXPERIMENTAL
Intervention: GEE Poisson model
Number of subjects: 50
Study 29096682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian binomial GLMM
Number of subjects: 50
Study 29096682 — intervention group
Group type: EXPERIMENTAL
Intervention: GLMM assuming binomial distribution
Number of subjects: 50
Study 29096682 — intervention group
Group type: EXPERIMENTAL
Intervention: GLMM assuming Poisson distribution
Number of subjects: 50
Study 29096682 — intervention group
Group type: COMPARATOR
Intervention: Log‐binomial model without adjustment for clustering
Number of subjects: 50
Study 24944135 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational football
Number of subjects: 26
Study 22460082 — intervention group
Group type: COMPARATOR
Intervention: Time-lapse incubator (TLI)
Number of subjects: 59
Study 20831134 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (RMGIC)
Number of subjects: 4
Study 20831134 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm sodium fluoride (F‐gel)
Number of subjects: 4
Study 20831134 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC
Number of subjects: 4
Study 20831134 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 4
Study 20831134 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate (CPP‐ACP)
Number of subjects: 4
Study 17506855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 45
Study 17506855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 50 mg (healthy volunteers)
Number of subjects: 45
Study 17506855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15677388 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitogenic environment (intervention group)
Number of subjects: 18
Study 15677388 — intervention group
Group type: COMPARATOR
Intervention: Obesogenic environment (control group)
Number of subjects: 18
Study 11894723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic OCs containing EE combined with DSG or GST
Number of subjects: 22
Study 11894723 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic OCs containing EE combined with GST or NGT
Number of subjects: 22
Study 11894723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic combination of EE and GST
Number of subjects: 22
Study 11894723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic OCs containing EE and GST
Number of subjects: 22
Study 11894723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic OCs containing EE and DSG
Number of subjects: 22
Study 11894723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OCs containing newer gonane progestogens
Number of subjects: 22
Study 10512908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI
Number of subjects: 43
Study 7859140 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin, 50 mg subcutaneously 3 times per week
Number of subjects: 352
Study 1777589 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antibiotic prophylaxis with trimethoprim-sulfamethoxasole
Number of subjects: 65
Study 1777589 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 65
Study 6352004 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2) every 3 weeks
Number of subjects: 80
Study 6352004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin
Number of subjects: 80
Study 31851158 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal therapy (TMT) consisting of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and radiotherapy
Number of subjects: 0
Study 31851158 — intervention group
Group type: COMPARATOR
Intervention: Bladder-sparing therapies (including partial cystectomy, radiation monotherapy, and radical transurethral resection)
Number of subjects: 0
Study 31851158 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 0
Study 30042516 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (WPC)
Number of subjects: 47
Study 30042516 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein concentrate (SPC)
Number of subjects: 47
Study 30042516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 47
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily low-molecular weight heparin
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring antifactor Xa activity levels
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Reexposure to asparaginase
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion to maintain platelet count >50×10/L
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of anticoagulation for line-associated thrombosis
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of anticoagulation for cerebral sinovenous thrombosis
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous access device insertion
Number of subjects: 0
Study 26907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of central venous access devices
Number of subjects: 0
Study 25025601 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga (IY) program, 6-week duration, twice per week
Number of subjects: 51
Study 25025601 — intervention group
Group type: COMPARATOR
Intervention: Usual-care waitlist control group
Number of subjects: 51
Study 22008735 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) + Gaboxadol (10 mg)
Number of subjects: 440
Study 22008735 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 440
Study 22008735 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) + Gaboxadol (5 mg)
Number of subjects: 440
Study 22008735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 20869711 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 282
Study 20869711 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 282
Study 17157479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser (LPL) irradiation immediately after operation (energy output 4 J/cm2, power density 50 mW, wavelength 637 nm)
Number of subjects: 120
Study 17157479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 4 mg dexamethasone (Dexason) into the internal pterygoid muscle
Number of subjects: 120
Study 17157479 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL irradiation supplemented by systemic dexamethasone (4 mg i.m. in deltoid region, followed by 4 mg intraorally 6h postoperatively)
Number of subjects: 120
Study 17157479 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative recommendations (cold packs, soft diet, etc.)
Number of subjects: 120
Study 17531730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar artery approach
Number of subjects: 100
Study 17531730 — intervention group
Group type: COMPARATOR
Intervention: Radial artery approach
Number of subjects: 100
Study 17531730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar artery approach with strong pulse
Number of subjects: 100
Study 17531730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar artery approach with weak pulse
Number of subjects: 100
Study 17531730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar artery and Radial artery approaches
Number of subjects: 100
Study 15205922 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET combined with CT
Number of subjects: 55
Study 15205922 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 55
Study 15205922 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 55
Study 11053821 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml aprotinin (Trasylol, Bayer AG)
Number of subjects: 20
Study 11053821 — intervention group
Group type: COMPARATOR
Intervention: 200 ml physiological saline solution
Number of subjects: 20
Study 9363289 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg per day)
Number of subjects: 44
Study 9363289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 1425866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 10
Study 6397218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg, three times daily
Number of subjects: 6
Study 6397218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine slow release 30 mg, twice daily
Number of subjects: 6
Study 6397218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31021123 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine integrated into primary care (ITM)
Number of subjects: 560
Study 31021123 — intervention group
Group type: COMPARATOR
Intervention: Quitline‐like phone counseling (QL)
Number of subjects: 560
Study 29784009 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-numeric and numeric information complemented by crowd-figure-pictograms
Number of subjects: 552
Study 29784009 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-numeric and numeric information
Number of subjects: 552
Study 29784009 — intervention group
Group type: COMPARATOR
Intervention: Non-numeric information (control group)
Number of subjects: 552